{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:35:06Z","timestamp":1790386506070,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T00:00:00Z","timestamp":1543881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/igo\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.vaccine.2018.11.072","type":"journal-article","created":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T17:56:32Z","timestamp":1544550992000},"page":"A99-A106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"S1","title":["An overview of the immunogenicity and effectiveness of current human rabies vaccines administered by intradermal route"],"prefix":"10.1016","volume":"37","author":[{"given":"Martine","family":"Denis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Knezevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Wilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiravat","family":"Hemachudha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Knopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.11.072_b0005","unstructured":"Recommendations for inactivated rabies vaccine for human use produced in cell substrates and embryonated eggs. In: WHO expert committee on biological standardization. Fifty-sixth report. Geneva, World Health Organization, Technical Report Series, No. 941, annex 2; 2005. p. 83\u2013132."},{"key":"10.1016\/j.vaccine.2018.11.072_b0010","first-page":"1","volume":"824","author":"WHO Expert Committee on Rabies","year":"1992","journal-title":"World Health Organ Tech Rep Ser"},{"issue":"5","key":"10.1016\/j.vaccine.2018.11.072_b0015","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/jtm.12228","article-title":"Vaccine and rabies immunoglobulin in cambodia: use and obstacles to use","volume":"22","author":"Tarantola","year":"2015","journal-title":"J Travel Med"},{"issue":"2","key":"10.1016\/j.vaccine.2018.11.072_b0020","doi-asserted-by":"crossref","first-page":"e0004448","DOI":"10.1371\/journal.pntd.0004448","article-title":"Reducing cost of rabies post exposure prophylaxis: experience of a tertiary care hospital in Pakistan","volume":"10","author":"Salahuddin","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"8694","key":"10.1016\/j.vaccine.2018.11.072_b0025","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/0140-6736(90)90488-Q","article-title":"Postexposure prophylaxis for rabies with antiserum and intradermal vaccination","volume":"335","author":"Chutivongse","year":"1990","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2018.11.072_b0030","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/1574891X10666150410130024","article-title":"Rabies in South Asia: fighting for elimination","volume":"10","author":"Chowdhury","year":"2015","journal-title":"Recent Pat Antiinfect Drug Discov"},{"issue":"85","key":"10.1016\/j.vaccine.2018.11.072_b0035","first-page":"309","article-title":"WHO position paper","volume":"32","author":"Rabies vaccines","year":"2010","journal-title":"Wkly Epidemiol Rec"},{"issue":"93","key":"10.1016\/j.vaccine.2018.11.072_b0040","first-page":"201","article-title":"WHO position paper","volume":"16","author":"Rabies vaccines","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2018.11.072_b0045","unstructured":"WHO Expert Consultation on Rabies 2004. First Report. WHO\u2014Technical Report Series 931; 2005. <http:\/\/www.who.int\/rabies\/trs931_%2006_05.pdf>."},{"issue":"6","key":"10.1016\/j.vaccine.2018.11.072_b0050","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.biologicals.2011.08.002","article-title":"Antigen content versus volume of rabies vaccines administered intradermally","volume":"39","author":"Dodet","year":"2011","journal-title":"Biologicals"},{"issue":"7","key":"10.1016\/j.vaccine.2018.11.072_b0055","doi-asserted-by":"crossref","first-page":"562","DOI":"10.4161\/hv.6.7.11934","article-title":"Assessing the relationship between antigenicity and immunogenicity of human rabies vaccines when administered by intradermal route: results of a metaanalysis","volume":"6","author":"Sudarshan","year":"2010","journal-title":"Hum Vaccin"},{"issue":"2","key":"10.1016\/j.vaccine.2018.11.072_b0060","first-page":"7","article-title":"Safety and immunogenicity of purified vero cell rabies vaccine versus purified chick embryo cell rabies vaccine using pre-exposure and post exposure regimen among healthy volunteers in San Lazaro Hospital","volume":"52","author":"Miranda","year":"2014","journal-title":"Phillippine J Int Med"},{"issue":"14","key":"10.1016\/j.vaccine.2018.11.072_b0065","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.vaccine.2004.09.027","article-title":"Reducing the cost of post-exposure rabies prophylaxis: efficacy of 0.1 ml PCEC rabies vaccine administered intradermally using the Thai Red Cross post-exposure regimen in patients severely exposed to laboratory-confirmed rabid animals","volume":"23","author":"Quiambao","year":"2005","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2018.11.072_b0070","doi-asserted-by":"crossref","first-page":"E122","DOI":"10.1086\/324087","article-title":"Failure of multiple-site intradermal postexposure rabies vaccination in patients with human immunodeficiency virus with low CD4+ T lymphocyte counts","volume":"33","author":"Tantawichien","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"30","key":"10.1016\/j.vaccine.2018.11.072_b0075","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1016\/j.vaccine.2005.03.007","article-title":"Potency requirements of rabies vaccines administered intradermally using the Thai Red Cross regimen: investigation of the immunogenicity of serially diluted purified chick embryo cell rabies vaccine","volume":"23","author":"Beran","year":"2005","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2018.11.072_b0080","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1080\/21645515.2015.1048938","article-title":"Comparison of safety and immunogenicity of 2 WHO prequalified rabies vaccines administered by one week, 4 site intra dermal regimen (4-4-4-0-0) in animal bite cases","volume":"11","author":"Narayana","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"10.1016\/j.vaccine.2018.11.072_b0085","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1586\/14760584.2014.971764","article-title":"Safety and immunogenicity of chromatographically purified Vero cell rabies vaccine for intradermal pre- and post-exposure rabies prophylaxis","volume":"13","author":"Tantawichien","year":"2014","journal-title":"Expert Rev Vaccines"},{"issue":"19","key":"10.1016\/j.vaccine.2018.11.072_b0090","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1016\/j.vaccine.2006.02.036","article-title":"Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen","volume":"24","author":"Ambrozaitis","year":"2006","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.vaccine.2018.11.072_b0095","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1016\/j.vaccine.2006.01.051","article-title":"Revision of the Thai Red Cross intradermal rabies post-exposure regimen by eliminating the 90-day booster injection","volume":"24","author":"Khawplod","year":"2006","journal-title":"Vaccine."},{"issue":"5","key":"10.1016\/j.vaccine.2018.11.072_b0100","first-page":"693","article-title":"Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine","volume":"78","author":"Briggs","year":"2000","journal-title":"Bull World Health Organ"},{"issue":"4","key":"10.1016\/j.vaccine.2018.11.072_b0105","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.1371\/journal.pntd.0000224","article-title":"A simplified 4-site economical intradermal post-exposure rabies vaccine regimen: a randomised controlled comparison with standard methods","volume":"2","author":"Warrell","year":"2008","journal-title":"PLoS Negl Trop Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2018.11.072_b0110","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1086\/344954","article-title":"Prospective immunogenicity study of multiple intradermal injections of rabies vaccine in an effort to obtain an early immune response without the use of immunoglobulin","volume":"35","author":"Khawplod","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"40","key":"10.1016\/j.vaccine.2018.11.072_b0115","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1016\/j.vaccine.2016.08.005","article-title":"A randomized non-inferiority clinical study to assess post-exposure prophylaxis by a new purified vero cell rabies vaccine (Rabivax-S) administered by intramuscular and intradermal routes","volume":"34","author":"Bose","year":"2016","journal-title":"Vaccine"},{"issue":"36","key":"10.1016\/j.vaccine.2018.11.072_b0120","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1016\/j.vaccine.2010.06.062","article-title":"Safety and efficacy of novel dermal and epidermal microneedle delivery systems for rabies vaccination in healthy adults","volume":"28","author":"Laurent","year":"2010","journal-title":"Vaccine"},{"issue":"29","key":"10.1016\/j.vaccine.2018.11.072_b0125","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1016\/j.vaccine.2010.04.090","article-title":"A preliminary study of chemo- and cytokine responses in rabies vaccine recipients of intradermal and intramuscular regimens","volume":"28","author":"Saraya","year":"2010","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2018.11.072_b0130","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.curtheres.2005.08.009","article-title":"Evaluation of a new five-injection, two-site, intradermal schedule for purified chick embryo cell rabies vaccine: a randomized, open-label, active-controlled trial in healthy adult volunteers in India","volume":"66","author":"Sudarshan","year":"2005","journal-title":"Curr Ther Res Clin Exp"},{"issue":"1","key":"10.1016\/j.vaccine.2018.11.072_b0135","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4161\/hv.26456","article-title":"Safety and immunogenicity study of a new purified chick embryo cell rabies vaccine Vaxirab-N (Pitman-Moore strain) manufactured in India","volume":"10","author":"Ashwath Narayana","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"10.1016\/j.vaccine.2018.11.072_b0140","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.4161\/hv.20471","article-title":"Evaluation of a one week intradermal regimen for rabies post-exposure prophylaxis: results of a randomized, open label, active-controlled trial in healthy adult volunteers in India","volume":"8","author":"Sudarshan","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2018.11.072_b0145","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2478\/abm-2010-0007","article-title":"Safety and immunogenicity of rabies pre- and postexposure intradermal regimens using Abhayrab, a purified vero cell rabies vaccine (PVRV) produced in India in healthy volunteers: Towards greater affordability of rabies prophylaxis","volume":"4","author":"Magpantay","year":"2010","journal-title":"Asian Biomed"},{"issue":"1","key":"10.1016\/j.vaccine.2018.11.072_b0150","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1086\/649211","article-title":"Postexposure rabies prophylaxis completed in 1 week: preliminary study","volume":"50","author":"Shantavasinkul","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"50","key":"10.1016\/j.vaccine.2018.11.072_b0155","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1016\/j.vaccine.2008.08.068","article-title":"A pilot study on intradermal vaccination of Japanese rabies vaccine for pre-exposure immunization","volume":"26","author":"Shiota","year":"2008","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2018.11.072_b0160","first-page":"145","article-title":"Evaluation of two intradermal vaccination regimens using purified chick embryo cell vaccine for post-exposure prophylaxis of rabies","volume":"14","author":"Madhusudana","year":"2001","journal-title":"Natl Med J India"},{"issue":"5","key":"10.1016\/j.vaccine.2018.11.072_b0165","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4161\/hv.2.5.3197","article-title":"Comparison of saftey and immunogenicity of purified chick embryo cell rabies vaccine (PCECV) and purified vero cell rabies vaccine (PVRV) using the Thai Red Cross intradermal regimen at a dose of 0.1 ML","volume":"2","author":"Madhusudana","year":"2006","journal-title":"Hum Vaccin"},{"issue":"8","key":"10.1016\/j.vaccine.2018.11.072_b0170","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.4161\/hv.29403","article-title":"Safety and Immunogenicity of purified chick embryo cell rabies vaccine (VaxiRab N) administered intradermally as post exposure prophylaxis","volume":"10","author":"Ravish","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"32","key":"10.1016\/j.vaccine.2018.11.072_b0175","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1016\/j.vaccine.2009.03.027","article-title":"Antibody response to an eight-site intradermal rabies vaccination in patients infected with Human Immunodeficiency Virus","volume":"27","author":"Sirikwin","year":"2009","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2018.11.072_b0180","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2310\/7060.2002.23189","article-title":"Four-site intradermal postexposure boosters in previously rabies vaccinated subjects","volume":"9","author":"Khawplod","year":"2002","journal-title":"J Travel Med"},{"issue":"4","key":"10.1016\/j.vaccine.2018.11.072_b0185","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1708-8305.1999.tb00524.x","article-title":"Immunogenicity of rabies postexposure booster injections in subjects who had previously received intradermal preexposure vaccination","volume":"6","author":"Jaijaroensup","year":"1999","journal-title":"J Travel Med"},{"issue":"5","key":"10.1016\/j.vaccine.2018.11.072_b0190","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/tax033","article-title":"Single visit rabies pre-exposure priming induces a robust anamnestic antibody response after simulated post-exposure vaccination: results of a dose-finding study","volume":"24","author":"Jonker","year":"2017","journal-title":"J Travel Med."},{"issue":"34","key":"10.1016\/j.vaccine.2018.11.072_b0195","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1016\/j.vaccine.2017.06.083","article-title":"A single center, open label study of intradermal administration of an inactivated purified chick embryo cell culture rabies virus vaccine in adults","volume":"35","author":"Recuenco","year":"2017","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.vaccine.2018.11.072_b0200","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.vaccine.2013.03.050","article-title":"Safety and immunogenicity of a new purified vero cell rabies vaccine (PVRV) administered by intramuscular and intradermal routes in healthy volunteers","volume":"31","author":"Kulkarni","year":"2013","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.vaccine.2018.11.072_b0205","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.vaccine.2013.01.035","article-title":"Rabies neutralizing antibody after 2 intradermal doses on days 0 and 21 for pre-exposure prophylaxis","volume":"31","author":"Wongsaroj","year":"2013","journal-title":"Vaccine."},{"issue":"19","key":"10.1016\/j.vaccine.2018.11.072_b0210","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1016\/j.vaccine.2011.12.028","article-title":"One clinic visit for pre-exposure rabies vaccination (a preliminary one year study)","volume":"30","author":"Khawplod","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2018.11.072_b0215","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1590\/S0034-89102010005000005","article-title":"Equivalence between pre-exposure schemes for human rabies and evaluation of the need for serological monitoring","volume":"44","author":"Cunha","year":"2010","journal-title":"Rev Saude Publica"},{"issue":"4","key":"10.1016\/j.vaccine.2018.11.072_b0220","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/INF.0b013e3181906351","article-title":"A three-year clinical study on immunogenicity, safety, and booster response of purified chick embryo cell rabies vaccine administered intramuscularly or intradermally to 12- to 18-month-old Thai children, concomitantly with Japanese encephalitis vaccine","volume":"28","author":"Pengsaa","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.vaccine.2018.11.072_b0225","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0035-9203(99)90309-7","article-title":"Immunogenicity and safety of low-dose intradermal rabies vaccination given during an Expanded Programme on immunization session in Viet Nam: results of a comparative randomized trial","volume":"93","author":"Lang","year":"1999","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2018.11.072_b0230","doi-asserted-by":"crossref","first-page":"S486","DOI":"10.1016\/S2222-1808(14)60495-3","article-title":"Epidemiology and prevention of animal bite and human rabies in a rural community-One health experiment","volume":"4","author":"Masthi","year":"2014","journal-title":"Asian Pac J Trop Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2018.11.072_b0235","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s10156-011-0286-2","article-title":"Immunogenicity of intradermal vaccination of Japanese rabies vaccine for preexposure immunization following WHO recommendation","volume":"18","author":"Yanagisawa","year":"2012","journal-title":"J Infect Chemother"},{"issue":"24","key":"10.1016\/j.vaccine.2018.11.072_b0240","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1016\/j.vaccine.2010.03.064","article-title":"Immunogenicity and safety study of Indirab: a Vero cell based chromatographically purified human rabies vaccine","volume":"28","author":"Sampath","year":"2010","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2018.11.072_b0245","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijid.2003.07.001","article-title":"Simulated post-exposure rabies vaccination with purified chick embryo cell vaccine using a modified Thai Red Cross regimen","volume":"8","author":"Madhusudana","year":"2004","journal-title":"Int J Infect Dis"},{"issue":"17\u201318","key":"10.1016\/j.vaccine.2018.11.072_b0250","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1016\/S0264-410X(02)00111-1","article-title":"Potency, sterility and immunogenicity of rabies tissue culture vaccine after reconstitution and refrigerated storage for 1 week","volume":"20","author":"Khawplod","year":"2002","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2018.11.072_b0255","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S1201-9712(02)90113-X","article-title":"Economical multi-site intradermal regimen with purified chick embryo cell vaccine (Rabipur) prevents rabies in people bitten by confirmed rabid animals","volume":"6","author":"Madhusudana","year":"2002","journal-title":"Int J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2018.11.072_b0260","first-page":"185","article-title":"Immunogenicity and safety of WHO-approved TRC-ID regimen with a chromatographically purified Vero cell rabies vaccine with or without rabies immunoglobulin in children","volume":"17","author":"Angsuwatcharakon","year":"2018","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2018.11.072_b0265","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1586\/14760584.2015.1011134","article-title":"30 Years of rabies vaccination with Rabipur: a summary of clinical data and global experience","volume":"14","author":"Giesen","year":"2015","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2018.11.072_b0270","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.tmaid.2007.07.004","article-title":"Preventing rabies with the Verorab vaccine: 1985\u20132005 Twenty years of clinical experience","volume":"5","author":"Toovey","year":"2007","journal-title":"Travel Med Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2018.11.072_b0275","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/21645515.2015.1085142","article-title":"Local infiltration of rabies immunoglobulins without systemic intramuscular administration: an alternative cost effective approach for passive immunization against rabies","volume":"12","author":"Bharti","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"10.1016\/j.vaccine.2018.11.072_b0280","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1080\/21645515.2016.1255834","article-title":"Injecting rabies immunoglobulin (RIG) into wounds only: a significant saving of lives and costly RIG","volume":"13","author":"Bharti","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.vaccine.2018.11.072_b0285","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.4161\/hv.28064","article-title":"Assessing safety and immunogenicity of post-exposure prophylaxis following interchangeability of rabies vaccines in humans","volume":"10","author":"Ravish","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.vaccine.2018.11.072_b0290","first-page":"147","article-title":"Clinical safety of intra dermal rabies vaccination (IDRV) with purified vero cell rabies vaccine (PVRV)","volume":"2","author":"Satapathy","year":"2011","journal-title":"Int J Pharma Bio Sci"},{"issue":"1","key":"10.1016\/j.vaccine.2018.11.072_b0295","first-page":"31","article-title":"Post-exposure prophylaxis for rabies with ERIG and IDRV in children","volume":"43","author":"Behera","year":"2011","journal-title":"J Commun Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2018.11.072_b0300","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1086\/656585","article-title":"A 4-site, single-visit intradermal postexposure prophylaxis regimen for previously vaccinated patients: experiences with >5000 patients","volume":"51","author":"Shantavasinkul","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"51","key":"10.1016\/j.vaccine.2018.11.072_b0305","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.1016\/j.vaccine.2009.09.036","article-title":"Rabies post-exposure prophylaxis with purified equine rabies immunoglobulin: one-year follow-up of patients with laboratory-confirmed category III rabies exposure in the Philippines","volume":"27","author":"Quiambao","year":"2009","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2018.11.072_b0310","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1371\/journal.pntd.0000243","article-title":"Rabies post-exposure prophylaxis in the Philippines: health status of patients having received purified equine F(ab')(2) fragment rabies immunoglobulin (Favirab)","volume":"2","author":"Quiambao","year":"2008","journal-title":"PLoS Negl Trop Dis."},{"issue":"4","key":"10.1016\/j.vaccine.2018.11.072_b0315","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0264-410X(88)90185-5","article-title":"NIH test, a problematic method for testing potency of inactivated rabies vaccine","volume":"6","author":"Barth","year":"1988","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2018.11.072_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajem.2014.09.026","article-title":"Paralytic rabies or postvaccination myelitis: a diagnostic dilemma","volume":"33","author":"Jain","year":"2015","journal-title":"Am J Emerg Med."},{"issue":"4","key":"10.1016\/j.vaccine.2018.11.072_b0325","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ajem.2015.01.037","article-title":"The importance of rabies immunoglobulin in postexposure prophylaxis","volume":"33","author":"Gozdas","year":"2015","journal-title":"Am J Emerg Med"},{"issue":"2","key":"10.1016\/j.vaccine.2018.11.072_b0330","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/1817-1745.139328","article-title":"Paralytic rabies following cat scratch and intra-dermal anti-rabies vaccination","volume":"9","author":"Gowda","year":"2014","journal-title":"J Pediatr Neurosci"},{"issue":"1","key":"10.1016\/j.vaccine.2018.11.072_b0335","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1086\/649873","article-title":"Failure of rabies postexposure prophylaxis in patients presenting with unusual manifestations","volume":"50","author":"Shantavasinkul","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"2015","key":"10.1016\/j.vaccine.2018.11.072_b0340","article-title":"Rabies encephalitis in a child: a failure of rabies post exposure prophylaxis?","volume":"14","author":"Tinsa","year":"2015","journal-title":"BMJ Case Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18316359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18316359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T02:28:30Z","timestamp":1569551310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18316359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":68,"alternative-id":["S0264410X18316359"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.11.072","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An overview of the immunogenicity and effectiveness of current human rabies vaccines administered by intradermal route","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.11.072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}